Uveitis

Uveitis:

Principal Investigator 2015 - 2015
An Open-Label, Non-Randomized, Single-Arm, Rollover Study to Continue Dosing of Gevokizumab in Subjects with Non Infectious Intermediate, Posterior, or Pan-Uveitis Who Have Controlled Ocular Inflammation After Receiving Study Drug in Study X052133

Principal Investigator, 2013 - 2015
EYEGUARD C- A RandomizEd, Double-masked, Placebo-controlled Study of the SafetY and Efficacy of GevokizUmAb in the TReatment of Subjects with Non-infectious IntermeDiate, Posterior, or Pan-uveitis Currently Controlled with Systemic Treatment

Principal Investigator, 2013 - 2015
EYEGUARD A- A RandomizEd, Double-masked, Placebo-controlled Study of the SafetY and Efficacy of GevokizUmAb in the TReatment of Active Non-infectious IntermeDiate, Posterior, or Pan-Uveitis